SS Innovations International (NASDAQ: SSII) reported record second-quarter 2026 revenue of $13.9 million, a 39.4% increase from $10 million in the same period last year, driven by a 30.4% rise in installations of its SSi Mantra surgical robotic system to 30 units. Gross profit climbed 20% to $7.1 million, yielding a gross margin of 50.9%. The company posted a net loss of $2.7 million, or $0.01 per diluted share, compared to a net loss of $0.3 million a year ago.
For the first half of 2026, revenue surged 65.6% to $25 million, with SSi Mantra installations up 47.4% to 56 systems. As of June 30, SS Innovations held $13.6 million in cash and cash equivalents, no long-term debt, and a cumulative installed base of 224 SSi Mantra systems across 12 countries.
Operationally, the company achieved 12,272 cumulative procedures using the SSi Mantra by June 30, including 175 telesurgeries. Notably, SS Innovations completed a robotic telesurgery spanning more than 13,600 miles between Colombia and India, demonstrating the system's remote capabilities.
Looking ahead, SS Innovations expects the U.S. Food and Drug Administration to complete its review of the company's 510(k) premarket notification for the SSi Mantra by the end of the first quarter of 2027. Additionally, management believes it can obtain European Union CE marking certification by the end of 2026. These regulatory milestones are critical for expanding into major markets and could significantly broaden the system's global adoption.
The company's focus on affordability and accessibility aligns with its mission to democratize robotic surgery. SS Innovations develops innovative surgical robotic technologies, including its proprietary SSi Mantra system and a suite of SSi Mudra instruments, which support various procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its cost-effective solutions.
The record revenue and installation growth indicate strong demand for the SSi Mantra, particularly in emerging markets where cost-effective robotic surgery is increasingly vital. The successful long-distance telesurgery underscores the system's reliability and potential for remote surgical assistance, which could be transformative for healthcare delivery in underserved regions.
While the company continues to incur net losses, its improving revenue trajectory and strategic regulatory progress position it for potential profitability. The absence of long-term debt provides financial flexibility to support ongoing operations and expansion efforts.
Investors and industry observers will be watching for FDA and CE marking outcomes, which could serve as catalysts for further growth. The company's forward-looking statements highlight expectations but also caution about risks and uncertainties that could affect actual results. Detailed risk factors are outlined in its filings with the SEC.
For more information on SS Innovations, visit its newsroom at https://ibn.fm/SSII. The full press release is available at https://ibn.fm/nTMso.
